Market Expansion Avinger’s ongoing development of product applications for coronary artery disease presents an opportunity to target cardiology centers and hospitals specializing in cardiac interventions, expanding their reach into the large and underserved market of coronary disease treatment.

Innovative Devices The launch of the Tigereye ST image-guided CTO crossing device indicates potential for sales in clinical centers focused on complex arterial blockages, emphasizing the adoption of advanced intravascular imaging tools to improve procedural outcomes.

Funding & Growth Recent funding rounds and a public offering suggest strong investor confidence, creating opportunities to leverage increased financial resources for strategic sales efforts and wider distribution channels within medical institutions.

Targeted Customer Base With a current revenue range of 10 to 25 million USD and an innovative product pipeline, Avinger’s primary markets include vascular and interventional clinics, providing tailored sales approaches aimed at specialists managing peripheral and coronary artery disease.

Technological Edge Avinger’s proprietary lumivascular platform and image-guided systems offer a competitive advantage that can be emphasized to healthcare providers seeking minimally invasive solutions with precise diagnostics and intervention capabilities to improve patient outcomes.